NXTC

6.4504.87%
MS

Michael S. Richman

Co-Founder, CEO, President & Director

Mr. Michael S. Richman, MSBA, Co-founded NextCure, Inc. since 2015 and has been its Chief Executive Officer, President & Director since October 2015. Mr. Richman served as the Chief Executive Officer and President of Amplimmune, Inc. from June 2008 to July 2015. He served as an Executive Vice President and Chief Operating Officer of MacroGenics, Inc. from April 2002 to May 2007. He joined MacroGenics, Inc. in 2002. He served as President and Chief Operating Officer of Amplimmune from May 2007 to June 2008. He has rich experience working in pharmaceutical research and business development. He helped found Amplimmune, a spinout from Johns Hopkins University and has since overseen its acquisition by MedImmune, the global biologics research and development arm of AstraZeneca, as a part of their global commitment to immunotherapy and developing novel medicines for patients. He served as President and Chief Executive Officer of AstraZeneca. Mr. Richman has held positions in companies including Chiron Corporation (now Novartis) and MacroGenics. He was employed at Eliance Biotechnology, Inc. He served as the Senior Vice President of Corporate Development Administration at Astra Zeneca (formerly, MedImmune, Inc. and MedImmune, LLC) from December 2000 to March 2002 and as its Vice President of Business Development from November 1996 to December 2000. While at MedImmune, Mr. Richman was responsible for all business development, licensing, intellectual property, legal affairs, project management and strategic planning functions and drove many significant transactions during that period. From 1985 to 1996, he served in various senior positions at Novartis and served as Director of corporate business development. He served as Manager of Business Development at Chiron Corporation from 1990 to 1992 and Manager of Intellectual Property from 1988 to 1990. He served as the Chairman of GenVec, Inc. since October 20, 2016 until June 16, 2017 and served as its Independent Director since April 22, 2015 until June 16, 2017. He has served on the supervisory board of Pieris GmbH since October 2014. He was Independent Director of Palvella Therapeutics, Inc. (Formerly, Pieris Pharmaceuticals, Inc.) since December 17, 2014 until December 13, 2024. He has been an Independent Director of Opexa Therapeutics, Inc. since June 16, 2006 until its acquisition by Acer Therapeutics in September 2017. He had been a Director of Madison Vaccines, Inc. since May 14, 2014 until 2024. He serves as Director at PharmaFrontiers Corp. since June 16, 2006. He serves as a Director of Amplimmune, Inc. He served as Director of Cougar Biotechnology, Inc. from June 8, 2006 to July 2009. He served as a Director of Acer Therapeutics Inc. Mr. Richman holds a MSBA degree in International Business from San Francisco State University with a concentration in International Business and a B.S. degree in Genetics and Molecular Biology from the University of California at Davis.

Positions